UroGen Pharma Ltd. Ordinary Shares
URGNUroGen Pharma Ltd. is a biotechnology company focused on developing innovative solutions for urological and uro-oncological conditions. The company's portfolio includes targeted therapies designed to improve treatment outcomes for patients with conditions such as bladder cancer and other genitourinary diseases. UroGen aims to leverage advanced drug delivery technologies to enhance safety and efficacy in urological treatments.
Company News
Wildcat Capital Management, the family office of late billionaire David Bonderman, completely exited its position in UroGen Pharma by selling 495,606 shares worth $6.79 million in Q3. Despite UroGen's impressive 113% one-year rally, the exit signals disciplined profit-taking rather than loss of confidence, as biotech winners often see valuation r...
UroGen Pharma granted restricted stock units to 14 new employees to support commercialization of Jelmyto and ZUSDURI, with up to 32,500 ordinary shares issuable upon vesting over three years.
UroGen Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in a fireside chat format, discussing their innovative cancer treatment technologies.
UroGen Pharma published a comprehensive review highlighting the clinical efficacy of ZUSDURI, an FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, demonstrating high complete response rates and a manageable safety profile.
A class action lawsuit has been filed against UroGen Pharma regarding its UGN-102 drug application, alleging misleading statements about clinical study design and FDA approval risks. The stock price dropped significantly after FDA advisory committee voted against drug approval.
